Modulation of the tumor cell death pathway by androgen receptor in response to cytotoxic stimuli

Journal of Cellular Physiology

Volumn 226, Issue 11, 2011, Pages 2731-2739

  Frezza, Michael ^a   Yang, Huanjie ^a   Dou, Q Ping ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; BICALUTAMIDE; BORTEZOMIB; CASPASE 3; CISPLATIN;

APOPTOSIS; ARTICLE; CANCER CELL; CELL DEATH; CELL STRAIN LNCAP; CYTOTOXICITY; ENZYME ACTIVATION; ENZYME ACTIVITY; EXPERIMENTAL MODEL; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MALE; NECROSIS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; TUMOR CELL; WILD TYPE;

ANILIDES; ANTINEOPLASTIC AGENTS; APOPTOSIS; BORONIC ACIDS; CASPASE 3; CELL LINE, TUMOR; CISPLATIN; HUMANS; MALE; NITRILES; PROSTATIC NEOPLASMS; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; RECEPTORS, ANDROGEN; TOSYL COMPOUNDS;

EID: 80051939467     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.22758     Document Type: Article

References (45)

1. Amaravadi RK, Thompson CB. 2007. The roles of therapy-induced autophagy and necrosis in cancer treatment. Clin Cancer Res 13: 7271-7279.
2. Attard G, Cooper CS, de Bono JS. 2009. Steroid hormone receptors in prostate cancer: A hard habit to break? Cancer Cell 16: 458-462.
3. Blank M, Shiloh Y. 2007. Programs for cell death: Apoptosis is only one way to go. Cell Cycle 6: 686-695.
4. Bonaccorsi L, Nosi D, Quercioli F, Formigli L, Zecchi S, Maggi M, Forti G, Baldi E. 2008. Prostate cancer: A model of integration of genomic and non-genomic effects of the androgen receptor in cell lines model. Steroids 73: 1030-1037.
5. Bruckheimer EM, Kyprianou N. 2000. Apoptosis in prostate carcinogenesis. A growth regulator and a therapeutic target. Cell Tissue Res 301: 153-162.
6. Bursch W, Ellinger A, Kienzl H, Torok L, Pandey S, Sikorska M, Walker R, Hermann RS. 1996. Active cell death induced by the anti-estrogens tamoxifen and ICI 164 384 in human mammary carcinoma cells (MCF-7) in culture: The role of autophagy. Carcinogenesis 17: 1595-1607.
7. Bursch W, Hochegger K, Torok L, Marian B, Ellinger A, Hermann RS. 2000. Autophagic and apoptotic types of programmed cell death exhibit different fates of cytoskeletal filaments. J Cell Sci 113: 1189-1198.
8. Chan FK, Shisler J, Bixby JG, Felices M, Zheng L, Appel M, Orenstein J, Moss B, Lenardo MJ. 2003. A role for tumor necrosis factor receptor-2 and receptor-interacting protein in programmed necrosis and antiviral responses. J Biol Chem 278: 51613-51621.
9. Chang C, Saltzman A, Yeh S, Young W, Keller E, Lee HJ, Wang C, Mizokami A. 1995. Androgen receptor: An overview. Crit Rev Eukaryot Gene Expr 5: 97-125.
10. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG, Sawyers CL. 2004. Molecular determinants of resistance to antiandrogen therapy. Nat Med 10: 33-39.
11. Chen D, Peng F, Cui QC, Daniel KG, Orlu S, Liu J, Dou QP. 2005. Inhibition of prostate cancer cellular proteasome activity by a pyrrolidine dithiocarbamate-copper complex is associated with suppression of proliferation and induction of apoptosis. Front Biosci 10: 2932-2939.
12. Chen D, Frezza M, Shakya R, Cui QC, Milacic V, Verani CN, Dou QP. 2007. Inhibition of the proteasome activity by gallium(III) complexes contributes to their anti prostate tumor effects. Cancer Res 67: 9258-9265.
13. Cohen MB, Rokhlin OW. 2009. Mechanisms of prostate cancer cell survival after inhibition of AR expression. J Cell Biochem 106: 363-371.
14. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, Bartsch G, Klocker H. 1994. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 54: 5474-5478.
15. Daniel KG, Chen D, Orlu S, Cui QC, Miller FR, Dou QP. 2005. Clioquinol and pyrrolidine dithiocarbamate complex with copper to form proteasome inhibitors and apoptosis inducers in human breast cancer cells. Breast Cancer Res 7: R897-908.
16. Davis R, Jia D, Cinar B, Sikka SC, Moparty K, Zhau HE, Chung LW, Agrawal KC, Abdel-Mageed AB. 2003. Functional androgen receptor confers sensitization of androgen-independent prostate cancer cells to anticancer therapy via caspase activation. Biochem Biophys Res Commun 309: 937-945.
17. de Bruin EC, Medema JP. 2008. Apoptosis and non-apoptotic deaths in cancer development and treatment response. Cancer Treat Rev 34: 737-749.
18. Degterev A, Boyce M, Yuan J. 2003. A decade of caspases. Oncogene 22: 8543-8567.
19. Diallo JS, Peant B, Lessard L, Delvoye N, Le Page C, Mes-Masson AM, Saad F. 2006. An androgen-independent androgen receptor function protects from inositol hexakisphosphate toxicity in the PC3/PC3(AR) prostate cancer cell lines. Prostate 66: 1245-1256.
20. Fulda S, Debatin KM. 2006. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 25: 4798-4811.
21. Furr BJ. 1996. The development of Casodex (bicalutamide): Preclinical studies. Eur Urol 29: 83-95.
22. Godfrey B, Lin Y, Larson J, Haferkamp B, Xiang J. 2010. Proteasomal degradation unleashes the pro-death activity of androgen receptor. Cell Res 20: 1138-1147.
23. Holdenrieder S, Stieber P. 2004. Apoptotic markers in cancer. Clin Biochem 37: 605-617.
24. Holler N, Zaru R, Micheau O, Thome M, Attinger A, Valitutti S, Bodmer JL, Schneider P, Seed B, Tschopp J. 2000. Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule. Nat Immunol 1: 489-495.
25. Hunter AM, LaCasse EC, Korneluk RG. 2007. The inhibitors of apoptosis (IAPs) as cancer targets. Apoptosis 12: 1543-1568.
26. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. 2008. Cancer statistics, 2008. CA Cancer J Clin 58: 71-96.
27. Kane RC, Bross PF, Farrell AT, Pazdur R. 2003. Velcade: US FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist 8: 508-513.
28. Kane RC, Dagher R, Farrell A, Ko CW, Sridhara R, Justice R, Pazdur R. 2007. Bortezomib for the treatment of mantle cell lymphoma. Clin Cancer Res 13: 5291-5294.
29. Kim R, Emi M, Tanabe K. 2006. The role of apoptosis in cancer cell survival and therapeutic outcome. Cancer Biol Ther 5: 1429-1442.
30. Lazebnik YA, Kaufmann SH, Desnoyers S, Poirier GG, Earnshaw WC. 1994. Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE. Nature 371: 346-347.
31. Libertini SJ, Tepper CG, Rodriguez V, Asmuth DM, Kung HJ, Mudryj M. 2007. Evidence for calpain-mediated androgen receptor cleavage as a mechanism for androgen independence. Cancer Res 67: 9001-9005.
32. Okada H, Mak TW. 2004. Pathways of apoptotic and non-apoptotic death in tumour cells. Nat Rev Cancer 4: 592-603.
33. Pelley RP, Chinnakannu K, Murthy S, Strickland FM, Menon M, Dou QP, Barrack ER, Reddy GP. 2006. Calmodulin-androgen receptor (AR) interaction: Calcium-dependent, calpain-mediated breakdown of AR in LNCaP prostate cancer cells. Cancer Res 66: 11754-11762.
34. Ricci MS, Zong WX. 2006. Chemotherapeutic approaches for targeting cell death pathways. Oncologist 11: 342-357.
35. Risek B, Bilski P, Rice AB, Schrader WT. 2008. Androgen receptor-mediated apoptosis is regulated by photoactivatable androgen receptor ligands. Mol Endocrinol 22: 2099-2115.
36. Sellers WR, Fisher DE. 1999. Apoptosis and cancer drug targeting. J Clin Invest 104: 1655-1661.
37. Sivanandam A, Murthy S, Chinnakannu K, Bai U, Kim SH, Barrack ER, Menon M, Reddy GP. 2010. Calmodulin protects androgen receptor from calpain-mediated breakdown in prostate cancer cells. J Cell Physiol. 2010 Nov 10. [Epub ahead of print]. PMID: 21069721.
38. Taplin ME. 2008. Androgen receptor: Role and novel therapeutic prospects in prostate cancer. Expert Rev Anticancer Ther 8: 1495-1508.
39. Taplin ME, Balk SP. 2004. Androgen receptor: A key molecule in the progression of prostate cancer to hormone independence. J Cell Biochem 91: 483-490.
40. Waller AS, Sharrard RM, Berthon P, Maitland NJ. 2000. Androgen receptor localisation and turnover in human prostate epithelium treated with the antiandrogen, casodex. J Mol Endocrinol 24: 339-351.
41. Yang H, Chen D, Cui QC, Yuan X, Dou QP. 2006. Celastrol, a triterpene extracted from the Chinese "Thunder of God Vine," is a potent proteasome inhibitor and suppresses human prostate cancer growth in nude mice. Cancer Res 66: 4758-4765.
42. Yang H, Murthy S, Sarkar FH, Sheng S, Reddy GP, Dou QP. 2008. Calpain-mediated androgen receptor breakdown in apoptotic prostate cancer cells. J Cell Physiol 217: 569-576.
43. Yeh S, Hu YC, Rahman M, Lin HK, Hsu CL, Ting HJ, Kang HY, Chang C. 2000. Increase of androgen-induced cell death and androgen receptor transactivation by BRCA1 in prostate cancer cells. Proc Natl Acad Sci USA 97: 11256-11261.
44. Zegarra-Moro OL, Schmidt LJ, Huang H, Tindall DJ. 2002. Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. Cancer Res 62: 1008-1013.
45. Zong WX, Ditsworth D, Bauer DE, Wang ZQ, Thompson CB. 2004. Alkylating DNA damage stimulates a regulated form of necrotic cell death. Genes Dev 18: 1272-1282.